• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

寻找靶向柔性CK2亚基界面的小分子抑制剂。

In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface.

作者信息

Bestgen Benoît, Belaid-Choucair Zakia, Lomberget Thierry, Le Borgne Marc, Filhol Odile, Cochet Claude

机构信息

Biology of Cancer and Infection, INSERM, U 1036, 38054 Grenoble, France.

Biology of Cancer and Infection, University Grenoble-Alpes (UGA), 38000 Grenoble, France.

出版信息

Pharmaceuticals (Basel). 2017 Feb 3;10(1):16. doi: 10.3390/ph10010016.

DOI:10.3390/ph10010016
PMID:28165359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5374420/
Abstract

Protein kinase CK2 is a tetrameric holoenzyme composed of two catalytic (α and/or α') subunits and two regulatory (β) subunits. Crystallographic data paired with fluorescence imaging techniques have suggested that the formation of the CK2 holoenzyme complex within cells is a dynamic process. Although the monomeric CK2α subunit is endowed with a constitutive catalytic activity, many of the plethora of CK2 substrates are exclusively phosphorylated by the CK2 holoenzyme. This means that the spatial and high affinity interaction between CK2α and CK2β subunits is critically important and that its disruption may provide a powerful and selective way to block the phosphorylation of substrates requiring the presence of CK2β. In search of compounds inhibiting this critical protein-protein interaction, we previously designed an active cyclic peptide (Pc) derived from the CK2β carboxy-terminal domain that can efficiently antagonize the CK2 subunit interaction. To understand the functional significance of this interaction, we generated cell-permeable versions of Pc, exploring its molecular mechanisms of action and the perturbations of the signaling pathways that it induces in intact cells. The identification of small molecules inhibitors of this critical interaction may represent the first-choice approach to manipulate CK2 in an unconventional way.

摘要

蛋白激酶CK2是一种四聚体全酶,由两个催化(α和/或α')亚基和两个调节(β)亚基组成。晶体学数据与荧光成像技术相结合表明,细胞内CK2全酶复合物的形成是一个动态过程。虽然单体CK2α亚基具有组成型催化活性,但众多CK2底物中的许多底物仅被CK2全酶磷酸化。这意味着CK2α和CK2β亚基之间的空间和高亲和力相互作用至关重要,其破坏可能提供一种强大且选择性的方式来阻断需要CK2β存在的底物的磷酸化。为了寻找抑制这种关键蛋白质 - 蛋白质相互作用的化合物,我们之前设计了一种源自CK2β羧基末端结构域的活性环肽(Pc),它可以有效拮抗CK2亚基相互作用。为了理解这种相互作用的功能意义,我们生成了细胞可渗透的Pc版本,探索其作用的分子机制以及它在完整细胞中诱导的信号通路的扰动。鉴定这种关键相互作用的小分子抑制剂可能代表了以非常规方式操纵CK2的首选方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/cbc042637a71/pharmaceuticals-10-00016-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/684c542bf5be/pharmaceuticals-10-00016-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/ce0a17bbe79d/pharmaceuticals-10-00016-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/d0b4eeca5760/pharmaceuticals-10-00016-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/d0122958a859/pharmaceuticals-10-00016-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/dee9fe793206/pharmaceuticals-10-00016-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/47454d743dcc/pharmaceuticals-10-00016-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/13612ffbd7c1/pharmaceuticals-10-00016-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/cbc042637a71/pharmaceuticals-10-00016-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/684c542bf5be/pharmaceuticals-10-00016-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/ce0a17bbe79d/pharmaceuticals-10-00016-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/d0b4eeca5760/pharmaceuticals-10-00016-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/d0122958a859/pharmaceuticals-10-00016-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/dee9fe793206/pharmaceuticals-10-00016-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/47454d743dcc/pharmaceuticals-10-00016-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/13612ffbd7c1/pharmaceuticals-10-00016-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f6d/5374420/cbc042637a71/pharmaceuticals-10-00016-g008.jpg

相似文献

1
In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface.寻找靶向柔性CK2亚基界面的小分子抑制剂。
Pharmaceuticals (Basel). 2017 Feb 3;10(1):16. doi: 10.3390/ph10010016.
2
The activity of CK2 in the extracts of COS-7 cells transfected with wild type and mutant subunits of protein kinase CK2.用蛋白激酶CK2的野生型和突变亚基转染的COS-7细胞提取物中CK2的活性。
Mol Cell Biochem. 2001 Nov;227(1-2):37-44.
3
Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.迈向选择性CK2α和CK2α'抑制剂:通过催化性CK2α'的自动展示开发新型全细胞激酶测定法。
J Pharm Biomed Anal. 2016 Mar 20;121:253-260. doi: 10.1016/j.jpba.2016.01.011. Epub 2016 Jan 8.
4
Development of a high-throughput screening-compatible assay to identify inhibitors of the CK2α/CK2β interaction.开发一种与高通量筛选兼容的检测方法,以鉴定CK2α/CK2β相互作用的抑制剂。
Anal Biochem. 2015 Jan 1;468:4-14. doi: 10.1016/j.ab.2014.09.003. Epub 2014 Sep 16.
5
First structure of protein kinase CK2 catalytic subunit with an effective CK2β-competitive ligand.首个蛋白激酶 CK2 催化亚基与有效 CK2β 竞争性配体的结构。
ACS Chem Biol. 2013 May 17;8(5):901-7. doi: 10.1021/cb3007133. Epub 2013 Mar 18.
6
A proteomics analysis of CK2β C2C12 cells provides novel insights into the biological functions of the non-catalytic β subunit.CK2β C2C12 细胞的蛋白质组学分析为非催化β亚基的生物学功能提供了新的见解。
FEBS J. 2019 Apr;286(8):1561-1575. doi: 10.1111/febs.14799. Epub 2019 Mar 18.
7
The regulatory beta subunit of protein kinase CK2 mediates formation of tetrameric CK2 complexes.蛋白激酶CK2的调节性β亚基介导四聚体CK2复合物的形成。
J Biol Chem. 2000 Feb 18;275(7):5003-10. doi: 10.1074/jbc.275.7.5003.
8
Dual effect of lysine-rich polypeptides on the activity of protein kinase CK2.富含赖氨酸的多肽对蛋白激酶CK2活性的双重作用。
J Cell Biochem. 2003 May 15;89(2):348-55. doi: 10.1002/jcb.10493.
9
Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.基于结构的蛋白激酶CK2亚基相互作用小肽抑制剂的设计
Biochem J. 2007 Dec 15;408(3):363-73. doi: 10.1042/BJ20070825.
10
Role of plant-specific N-terminal domain of maize CK2β1 subunit in CK2β functions and holoenzyme regulation.玉米 CK2β1 亚基的植物特异性 N 端结构域在 CK2β 功能和全酶调控中的作用。
PLoS One. 2011;6(7):e21909. doi: 10.1371/journal.pone.0021909. Epub 2011 Jul 15.

引用本文的文献

1
Recent Advances in the Discovery of CK2 Inhibitors.CK2抑制剂发现方面的最新进展。
ACS Omega. 2024 May 3;9(19):20702-20719. doi: 10.1021/acsomega.3c10478. eCollection 2024 May 14.
2
Development of small cyclic peptides targeting the CK2α/β interface.靶向 CK2α/β 界面的小型环状肽的开发。
Chem Commun (Camb). 2022 Apr 12;58(30):4791-4794. doi: 10.1039/d2cc00707j.
3
Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.发现全酶破坏化学品作为底物选择性 CK2 抑制剂。

本文引用的文献

1
Underlying mechanisms of cyclic peptide inhibitors interrupting the interaction of CK2α/CK2β: comparative molecular dynamics simulation studies.环肽抑制剂阻断CK2α/CK2β相互作用的潜在机制:比较分子动力学模拟研究
Phys Chem Chem Phys. 2016 Apr 7;18(13):9202-10. doi: 10.1039/c5cp06276d.
2
Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity.乳腺癌中的蛋白激酶CK2:CK2β调节亚基在上皮可塑性中占据核心地位。
Cell Mol Life Sci. 2015 Sep;72(17):3305-22. doi: 10.1007/s00018-015-1929-8. Epub 2015 May 20.
3
Effects of the knockdown of death-associated protein 3 expression on cell adhesion, growth and migration in breast cancer cells.
Sci Rep. 2019 Nov 4;9(1):15893. doi: 10.1038/s41598-019-52141-5.
4
Efficient development of stable and highly functionalised peptides targeting the CK2α/CK2β protein-protein interaction.靶向CK2α/CK2β蛋白质-蛋白质相互作用的稳定且高度功能化肽的高效开发。
Chem Sci. 2019 Apr 12;10(19):5056-5063. doi: 10.1039/c9sc00798a. eCollection 2019 May 21.
5
2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.2-氨基噻唑衍生物作为蛋白激酶 CK2 的选择性别构调节剂。2. 基于结构的优化及对别构作用模式特异性的研究。
J Med Chem. 2019 Feb 28;62(4):1817-1836. doi: 10.1021/acs.jmedchem.8b01765. Epub 2019 Feb 13.
6
An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2.关于一个新兴靶点的最新观点:第八届蛋白激酶CK2国际会议精选论文
Pharmaceuticals (Basel). 2017 Mar 23;10(2):33. doi: 10.3390/ph10020033.
死亡相关蛋白3表达敲低对乳腺癌细胞黏附、生长和迁移的影响。
Oncol Rep. 2015 May;33(5):2575-82. doi: 10.3892/or.2015.3825. Epub 2015 Mar 2.
4
The protein kinase CK2(Andante) holoenzyme structure supports proposed models of autoregulation and trans-autophosphorylation.蛋白激酶 CK2(Andante)全酶结构支持自动调节和转自磷酸化的拟议模型。
J Mol Biol. 2014 May 1;426(9):1871-82. doi: 10.1016/j.jmb.2014.02.018. Epub 2014 Mar 1.
5
First structure of protein kinase CK2 catalytic subunit with an effective CK2β-competitive ligand.首个蛋白激酶 CK2 催化亚基与有效 CK2β 竞争性配体的结构。
ACS Chem Biol. 2013 May 17;8(5):901-7. doi: 10.1021/cb3007133. Epub 2013 Mar 18.
6
Kinase CK2 inhibition: an update.激酶 CK2 抑制:最新进展。
Curr Med Chem. 2013;20(5):671-93. doi: 10.2174/092986713804999312.
7
Protein kinase CK2 inhibitors: a patent review.蛋白激酶 CK2 抑制剂:专利研究综述。
Expert Opin Ther Pat. 2012 Sep;22(9):1081-97. doi: 10.1517/13543776.2012.717615.
8
Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction.CK2 激酶亚基的失衡表达足以通过诱导 Snail1 来驱动上皮-间充质转化。
Oncogene. 2013 Mar 14;32(11):1373-83. doi: 10.1038/onc.2012.165. Epub 2012 May 7.
9
ATP site-directed inhibitors of protein kinase CK2: an update.蛋白激酶 CK2 的 ATP 位点定向抑制剂:最新进展。
Curr Top Med Chem. 2011;11(11):1340-51. doi: 10.2174/156802611795589638.
10
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.发现和 SAR 研究 5-(3-氯苯氨基)苯并[c][2,6]萘啶-8-羧酸(CX-4945),一种用于癌症治疗的首个临床阶段蛋白激酶 CK2 抑制剂。
J Med Chem. 2011 Jan 27;54(2):635-54. doi: 10.1021/jm101251q. Epub 2010 Dec 21.